Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment-Reference-Cited by-同舟云学术

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

Published:2016-11-29 Issue:8 Volume:56 Page:915-924
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Clemens Pamela L.,Yan Xiaoyu,Lokhorst Henk M.,Lonial Sagar,Losic Nedjad,Khan Imran,Jansson Richard,Ahmadi Tahamtan,Lantz Kristen,Zhou Honghui,Puchalski Thomas,Xu Xu Steven

Funder

Janssen Research and Development, LLC

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-016-0477-1/fulltext.html

Reference21 articles.

1. Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000–2010. Clin Lymphoma Myeloma Leuk. 2010;10:424–42.

2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

3. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.